Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

This phase I/II trial tests the safety, side effects and effectiveness of radioembolization with yttrium-90 (Y-90) in patients with early stage renal cell carcinoma. Y-90 is a radioactive chemical that is incorporated into millions of very tiny glass spheres. These spheres are injected into the artery that feeds the cancer. This process is called radioembolization. Y-90 radioembolization may be a safe and effective treatment for patients with early stage renal cell carcinoma.

Trial Details

NCT ID

NCT06432036

Phase

PHASE1 / PHASE2

Sponsor

Jonsson Comprehensive Cancer Center

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

Angiogram
Biospecimen Collection
Computed Tomography
Radioembolization
Single Photon Emission Computed Tomography
Survey Administration

Locations (sample)

Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

Participants must be aged ≥ 18 years at the time of screening
Written informed consent and any locally required authorization (e.g., Health Insurance Portability and accountability Act) obtained from the patie…
Life expectancy ≥ 12 months
RCC, diagnosed by radiographic imaging and histology

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →